Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTR5A | P47898 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467975 | 0.88 | KDM4E (0.35) | KDM4EALDH1A1HTR5APIM1 | |
| SCHEMBL5468887 | 0.86 | ALDH1A1 (0.48) | KDM4EALDH1A1HTR5A | |
| SCHEMBL19277490 | 0.81 | KDM4E (0.40) | KDM4EALDH1A1HTR5APIM1 | |
| SCHEMBL15499270 | 0.81 | KDM4E (0.36) | KDM4EALDH1A1HTR5APIM1 | |
| SCHEMBL25176236 | 0.76 | ALDH1A1 (0.42) | KDM4EALDH1A1HTR5A | |
| SCHEMBL16841705 | 0.76 | ALDH1A1 (0.38) | KDM4EALDH1A1HTR5A | |
| SCHEMBL24456723 | 0.76 | ALDH1A1 (0.38) | KDM4EALDH1A1HTR5A | |
| SCHEMBL18226053 | 0.76 | KDM4E (0.38) | KDM4EALDH1A1HTR5A | |
| SCHEMBL15262863 | 0.76 | KDM4E (0.38) | KDM4EALDH1A1HTR5A | |
| SCHEMBL5474903 | 0.74 | ALDH1A1 (0.46) | KDM4EALDH1A1HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-02-24 | — | — | US | disclosed |
| EP-1444210-A1 | QUNAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2003040108-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | KDM4E 2435/4885ALDH1A1 3334/4885HTR5A 1173/4885 |
| US-20050043336-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | KDM4E 2435/4885ALDH1A1 3334/4885HTR5A 1173/4885 |
| US-20070082921-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | KDM4E 2238/4885ALDH1A1 4094/4885HTR5A 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.